Maximizing the efficacy of antibiotic therapy
|
|
- Dina Horn
- 5 years ago
- Views:
Transcription
1 Community Acquired Pneumonia Maximizing the efficacy of antibiotic therapy João Gonçalves Pereira, MD, PhD ICU Director Hospital Vila Franca Xira
2 Antibiotics and Pneumonia Survival in Bacteremic Pneumococcal Bacteremia Treated with Penicillin or Serum Austrian Ann Intern Med 1964;60:759
3 Antibiotics and Pneumonia Time until start of antibiotic therapy (CAP) Community acquired Sepsis Houck Arch Intern Med 2004; 164: 637 N = % CAP Povoa CCM 2009;37:410 Kumar, A Virulence 2014; 5:1
4 Antibiotics and Pneumonia Pneumonia Bundle Wiemken Semin Respir Crit Care Med 2012;33:213
5 Early antibiotics and outcome Author n Setting Odds Ratio (death) Author n Setting Odds Ratio (death) Gaieski (Crit Care Med 2010; 38:1045) 261 ED (Shock) First hour OR 0.30 No difference independent of De Groot (Critical Care 2015; 19:194) ED First hour PIRO score OR 0.62 Daniels (Emerg Med J 2010; doi: ) 567 Whole hospital Aggressive antibiotic therapy Surgical ICU: Beforeafter First vs second hour OR 0.59 Hranjec (Lancet Infect Dis 2012;12:774) 201 OR for mortality 2.5 Kumar (Crit Care Med 2006;34:1589) 2154 ED (Shock) Hospital-acquired No difference in mortality up to Puskarich (Crit Care Med 2011;39:12066) 372 Appelboam (Crit Care 2010;14:50) 375 Whole surgical hospital infections First hour 6h after OR diagnostic 0.74 First 3h No improvement OR 0.86 with decrease Levy Villela (Crit Care (Am Med J Emerg 2010; Med 38:1) 2014;32:7) Multi-centre ED admitted to the ICU in time to antibiotics (5h to 3h) Barie Pelletier(Surg Infect (Larchmt) Infect (Larch) 2005;6:41) 1999;134:1300) Surgical Surgical ICU patients Per hour No difference delay h,>12h, >24h Ferrer Castellanos-Ortega (Crit Care Med (Crit Care Med 2014;42:1749) Multi-centre ED: Before-after 2010;38:1036) Progressive Early antibiotics increase in OR risk 0.68, per hour p=0.11 ( ) Jalili (Acta Med Iran 2013; 51:454) 145 ED (sepsis) First 2h Inappropriate Davies (Shock 2014;42:185) 7158 Surgical patients OR 0.44 vs. appropriate OR 1.0 No difference in a metanalysis (11 studies included). OR 1.16 Sterling Crit Care Med. 2015;43:1907
6 Accuracy of sepsis diagnosis Infection rate in patients with presumed sepsis upon presentation Klein Klouwenberg Crit Care 2015;19:319 Over 50% of patients with suspected pneumonia probably did not had infection Antibiotics are of no use if patients are not infected (harm?)
7 Antibiotics and Pneumonia Pneumonia Bundle Better diagnostic tools Early directed therapy Adequate dose 1 2 Reassess diagnostic PK and antibiotic dose Response to therapy Minimize antibiotic exposure 3 Wiemken Semin Respir Crit Care Med 2012;33:213
8 Pharmacokinetics Antibiotics Absorption Distribution Elimination PK Effect of the antibiotic at the site of infection Concentration at Infection Site Pathogen MIC/MBC PD Bacterial Killing Toxicity Dose antibiotics to maximize its exposure to bacteria Craig WA - CID 1998; 26.1
9 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Metronidazol 4 Area under the concentration curve Azithromycin 2 Fluoroquinolones Glycopeptides Log 10 CFU/ ml Log 10 CFU/ ml MIC T>MIC Beta-lactams Carbapenems Control ¼ x MIC 1 x MIC 4 x MIC 16 x MIC 64 x MIC Time (hours)
10 Two fold variability of PK parameters (Vd and Cl) Usually increase No clear correlation with clinical parameters Augmented Volume of Distribution Augmented renal Clearance Meropenem ARC Imipenem Piperacillin Cefpirome Cefepime Ceftazidime Volume of Distribution (L) Udy, Baptista Crit Care Med 2014; 42:520
11 Dose of Antibiotics Obesity Longo. Pharmacoepidemiology and Drug Safety 2013; 22: 970
12 Concentration Patterns of Antimicrobial Activity C max :MIC Aminoglycosides MIC and resistance AUC:MIC Vancomycin Fluoroquinolones Concentration C max :MIC Aminoglycosides MIC=0.5 AUC:MIC Vancomycin Fluoroquinolones T>MIC MIC=1 Beta-lactams Carbapenems Time T>MIC Beta-lactams Carbapenems Time Increase in MIC 0.5 1mg/L: Bacteria remain sensitive. However AUC:MIC and Cmax:MIC decrease to one half; T>MIC also decreases Changes in PK may impact clinical efficacy
13 Bacterial load and mortality Pneumococcal Pneumonia n=353 Rt-PCR positive 26,3% (36,5% positive BC) Septic shock OR 6.29 Mech. Ventilation OR 7.96 Mortality OR 7.08 Patients with positive Rt-PCR Bacterial Load > 10 3 cop/ml (29%) Shock OR 8 Mech. Vent OR 10.5 Mortality OR 5.4 Rello Chest 2009;136:832
14 Selection of initial antibiotics Single vs. double Use of a macrolide in CAP Sligl Crit Care Med 2014; 42:420
15 Selection of initial antibiotics Single vs. double The CAPUCI study No Shock Shock Survival HR 1.69 (95%CI ) Rodriguez Crit Care Med 2007;35:1493 Macrolides p = 0.99 Death HR 0.48 (95%CI ) Martin-Loeches Intensive Care Med 2010; 36:612
16 Clinical Success (%) Dose of Antibiotics Clinical Success by PSI Class n= n= n= n= n= mg 500 mg 84.4 n=32 80 Class I/II Class III Class IV Patients in Each PSI *Clinically evaluable patients at the 7- to 14-day post therapy visit Dunbar Clin Infect Dis. 2003;37:752
17 PK/PD guided dose Lower adjusted 90d mortality (p=0.02) Lower LOS (3.9 vs. 5d, p<0.001) Lower Costs ($2485 vs. $3281, p=0.02) Frei, BMC Infect Dis 2011,11: 188
18 N= ICUs BLING II study APACHE II day survival 74.3% vs. 72.5% HR 0.91 ( ) Clinical success Cefepime or ceftazidime AUIC 250 Cure 79% vs. 33%; P = T>MIC of 100% Cure 82% vs. 33%; P = Mckinnon. Int J Antimicrob Agents 2008; 31: 345 Dulhunty Am J Resp Crit Care Med 2015; 192: 1298
19 Log 10 cfu/ml Log 10 cfu/ml Optimization of minimum concentration/mic ratio Log 10 cfu/ml Log 10 cfu/ml Placebo Time (days) T>MIC=100% & Cmin/MIC= Time (days) T>MIC=84% T>MIC=100% Cmin/MIC=1.7+ tobramycin Time (days) Time (days) Tam Antimicrob Agents Chemother 2005; Wild type Amp C mutant
20 Vasopressors Cardiac output Diuresis Dose modulation: A new concept of antibiotic therapy in the critically ill patient?,, Joao Goncalves-Pereira MD a,, José-Artur Paiva MD, PhD b a Polyvalent Intensive Care Unit, São Francisco Xavier Hospital, CHLO, Estrada do Forte do Alto do Duque, Lisboa, Portugal Critically ill septic patient b Emergency and Intensive Care Department, Centro Hospitalar São João, Medical School, University of Porto, Porto, Portugal Keywords: Antibiotics; Pharmacokinetics; Dose; Modulation; Intensive care unit Large Volume of Distribution Renal or Hepatic failure Initial High Loading Dose Increased Clearance 2012 Elsevier Inc. All rights reserved. (measure Cr Clearance) Large volume resuscitation Invasive Ventilation Surgical procedure Abstract Considerable evidence has shown that adequate antibiotic therapy is of utmost importance in the critically ill septic patient. However, antibiotic concentration may be insufficient early in infection course. We propose the concept of dose modulation, meaning front-line variability of antibiotic dose, according to patient and microorganism characteristics, followed by its reduction after clinical response and patient recovery. Therefore, dose modulation means concentrating No Yes the largest weight of antibiotics at the front-end, when the microbial load ishigher and the pharmacokinetic changes poses the highest risk of underdosing and nibbling off antibiotic dose, when the sepsis syndrome isimproving, guided by pharmacokinetic and pharmacodynamic data. Adjust Dose accordingly 1. Adequate antibiotic therapy: drug but also dose selection Maintain High Dose The accumulation of evidence that both front-line antibiotic inappropriateness and late appropriateness had significant impact on the outcome of infections in severe sepsis and septic shock patients led to the concept of Reassess after 48-72h Any of: Bacteria with a low MIC Normalization of (measured) Cr Clearance Sepsis resolution Funding: None. Competing interests: None declared. Authors Contributions: JG-P and J-AP both search literature, developed the concept, analyzed, data and wrote the manuscript. Corresponding author. Unidade de Cuidados Intensivos Polivalente, Hospital de São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Estrada do Forte do Alto do Duque, Lisboa, Portugal. Tel.: /5; fax: addresses: joaogpster@gmail.com (J. Goncalves-Pereira), jarturpaiva@gmail.com (J.-A. Paiva). antibiotic de-escalation, meaning that a large-spectrum antibiotic regimen should immediately be started front-line to assure coverage of the pathogen and clinical success. Combination antibiotic therapy has also been proposed in order to enlarge antibacterial spectrum and it may improve patient outcomes, especially in septic shock patients [1]. In parallel, antibiotic streamlining should be done as soon as there is evidence of clinical response and microbiological results are available, to reduce antibiotic pressure and avoid the emergence of antimicrobial resistance [2]. This has been shown to be safe in critically ill patients [3]. Several authors also pointed out that not only should antibiotic therapy be appropriate and early Adjust but also antibiotic Dose dose should be maximized to ensure adequate bactericidal concentration as soon as possible [4,5]. However, the concept ofgonçalves-pereira dose maximization isill-defined Crit Care. and, in our opinion, did not 2013;28:341 translate into the clinical arena.
21 Accumulation and Toxicity Ceftriaxone 2 g/d Increase 2-3* from D1 to D7 Cr Cl >50 ml/min <50 ml/min Day 1 19,5 μg/ml 46,5 μg/ml Day7 38,5 μg/ml 125 μg/ml Heinemeyer Int Care Med 1990; 16; 448 Betalactamin-induced central nervous side effects include confusion, disturbances of behaviour, hallucinations, asterixis, myoclonic jerks, and generalised convulsive or nonconvulsive seizures. Those are probably underreported but may contribute to morbidity and mortality. Chatellier Int Care Med 2002; May promote mitochondrial damage and shutdown. May interfere with mitochondrial biogenesis and delay recovery. Singer. Plos Med e167
22 Duration of Antimicrobial Activity Reduction of exposure 3-7 d vs d No difference in outcomes
23 "I see no hope for the future of our people if they are dependent on the frivolous youth of today, for they are reckless beyond words. When I was young, we were taught to be discreet, respectful of elders, but the present youth are exceedingly disrespectful and impatient." Hesiod, 700 BC
Maximizing the efficacy of antibiotic therapy
Community Acquired Pneumonia Maximizing the efficacy of antibiotic therapy João Gonçalves Pereira, MD, PhD ICU Director Hospital Vila Franca Xira Antibiotics and Pneumonia Survival in Bacteremic Pneumococcal
More informationDETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams
DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationPharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient
Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationAntimicrobial therapy in critical care
Antimicrobial therapy in critical care KARLEE JOHNSTON LEAD PHARMACIST DIVISION OF CRITICAL CARE CANBERRA HOSPITAL AND HEALTH SERVICE Outline 1. Let s talk about sepsis 2. PK/PD considerations 3. Selecting
More informationEarly Antibiotics for Sepsis and Septic Shock: A Gold Standard
Early Antibiotics for Sepsis and Septic Shock: A Gold Standard Anand Kumar MD, FRCPC, FCCP, FCCM Professor of Medicine University of Manitoba Health Sciences Centre St. Boniface Hospital Winnipeg, Manitoba
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationDoes Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock?
References and Literature Grading Does Early and Appropriate Antibiotic Administration Improve Mortality in Emergency Department Patients with Severe Sepsis or Septic Shock? (9/6/2015) 1. Dellinger, R.P.,
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationDOES TIMING OF ANTIBIOTICS IMPACT OUTCOME IN SEPSIS? Saravana Kumar MD HEAD,DEPT OF EM,DR MEHTA S HOSPITALS CHENNAI,INDIA
DOES TIMING OF ANTIBIOTICS IMPACT OUTCOME IN SEPSIS? Saravana Kumar MD HEAD,DEPT OF EM,DR MEHTA S HOSPITALS CHENNAI,INDIA drsaravanakumar.ep@gmail.com JOINT SECRETARY RECOMMENDATIONS: INITIAL RESUSCITATION
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationAntimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill
Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Arthur RH van Zanten, MD PhD Internist-intensivist Department of Intensive care Gelderse Vallei Hospital, Ede The Netherlands
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationICU Volume 14 - Issue 4 - Winter 2014/ Matrix
ICU Volume 14 - Issue 4 - Winter 2014/2015 - Matrix Antibiotic Management in the ICU Eleni Patrozou ******@***gmail.com Intensivist - Hygeia Hospital, Athens, Greece Infectious Diseases Division - Alpert
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationCombating Antimicrobial Resistance with Extended Infusion Beta-lactams. Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident
Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material
More informationDisclosure. Objectives. Combating Antimicrobial Resistance with Extended Infusion Beta-lactams
Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More information2016 Updates to the Hospital Acquired- and Ventilator Associated-Pneumonia Guidelines
2016 Updates to the Hospital Acquired- and Ventilator Associated-Pneumonia Guidelines Janessa M. Smith, PharmD, BCPS Clinical Pharmacy Specialist, Infectious Diseases The Johns Hopkins Hospital Objectives
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More information10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017
10 Golden rules of Antibiotic Stewardship in ICU Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 golden rules of Antibiotic Stewardship in the ICU ID, Pharma & Micro advice
More informationHigh Risk Emergency Medicine. Antibiotic Pitfalls
High Risk Emergency Medicine Antibiotic Pitfalls David, MD MS Assistant Professor Department of Emergency Medicine University of California, San Francisco I. Antibiotic Resistance Development of resistance
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC
ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC PREFACE INTRODUCTION The wide use and frequent misuse of antimicrobials in all countries has resulted in the emergence of drug resistance,
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationPercent Time Above MIC ( T MIC)
8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationSystematic Review of Clinical PK-PD Studies of Antibacterials. Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton
Systematic Review of Clinical PK-PD Studies of Antibacterials Alex McAleenan Julian Higgins Alasdair MacGowan William Hope Johan Mouton Background It has been suggested that there are problems with current
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationSystemic Antimicrobial Prophylaxis Issues
Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical
More informationSepsis. ...striking a balance. Dr Ron Daniels.
Sepsis...striking a balance Dr Ron Daniels Fellow: NHS Improvement Faculty Chair: United Kingdom Sepsis Group, Sepsis Trust & UK SSC Sepsis as a Global Emergency Committee, Global Sepsis Alliance Midland
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationAntibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals
Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Tom Dilworth, PharmD Aurora Health Care thomas.dilworth@aurora.org Objectives Describe the pharmacokinetics and pharmacodynamics
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationP< cells/µl mg/dl P<0.01 P<0.01
Technical Reports Judicious Use of s for Pediatric Infection Global Strategies to Prevent the Increase of Bacterial Resistance Kazunobu OUCHI Principle of antimicrobial therapy in children is to select
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationNUOVE IPOTESI e MODELLI di STEWARDSHIP
Esperienze di successo di antimicrobial stewardship Bologna, 18 novembre 2014 NUOVE IPOTESI e MODELLI di STEWARDSHIP Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Interventions
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationUpdate on PK/PD of antibiotics applied to critically ill patients: Focus on β-lactams and vancomycin
Update on PK/PD of antibiotics applied to critically ill patients: Focus on β-lactams and vancomycin Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Center for Clinical Pharmacy Louvain Drug
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationUse of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections
SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,
More informationLa sepsi Il ruolo dell antibiotico terapia
Congresso Nazionale AcEMC Fermo 11-12 Maggio 2017 La sepsi Il ruolo dell antibiotico terapia Michele Bartoletti Infectious Disease Unit - Sant Orsola Hospital, Bologna, Italy Disclosures: none Epidemiology
More informationResponsible use of antibiotics
Responsible use of antibiotics Uga Dumpis MD, PhD Department of Infectious Diseases and Infection Control Pauls Stradiņs Clinical University Hospital Challenges in the hospitals Antibiotics are still effective
More informationOptimising treatment based on PK/PD principles
Optimising treatment based on PK/PD principles Paul M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy Louvain Drug Research Institute Catholic University of Louvain Brussels,
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 09:00 09:20 Registration
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationUpdate on Therapeutic Drug Monitoring - Aminoglycosides. Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015
Update on Therapeutic Drug Monitoring - Aminoglycosides Antimicrobial Stewardship Forum Cardiff Nov. 2nd 2015 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust What are common
More informationIntra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018
Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection
More informationDATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
More informationMANAGING ANTIBIOTIC THERAPY
MANAGING ANTIBIOTIC THERAPY ITS MORE THAN JUST ABOUT THE S AND THE R Larry M. Bush, MD, FACP Affiliated Professor of Biomedical Science Charles E. Schmidt College of Medicine Florida Atlantic University
More informationPharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens
Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationContinuous beta-lactam infusion in critically ill patients: the clinical evidence
Abdul-Aziz et al. Annals of Intensive Care 2012, 2:37 REVIEW Open Access Continuous beta-lactam infusion in critically ill patients: the clinical evidence Mohd H Abdul-Aziz 1, Joel M Dulhunty 1,2*, Rinaldo
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 Time Topic/Activity
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More information